Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2004
03/18/2004WO2004022590A2 Immunogenic muc1 glycopeptides
03/18/2004WO2004022588A1 Variants of the major allergen phl p 1 from timothy grass
03/18/2004WO2004022094A1 Allergy vaccines
03/18/2004WO2004022093A1 Whole bacterial cells as immune modulator
03/18/2004WO2004022092A2 Flagellin peptides as adjuvants for vaccines
03/18/2004WO2004022084A1 A method of modulating cellular activity and molecules for use therein
03/18/2004WO2004021999A2 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
03/18/2004WO2004021994A2 Cancer therapy using whole glucan particles and antibodies
03/18/2004WO2004021977A2 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
03/18/2004WO2004021772A2 Immune cloning and uses thereof
03/18/2004WO2004015098A3 Rhesus epithelial cell adhesion molecule, nucleic acid encoding the same, and uses thereof
03/18/2004WO2004009116A3 Hapten-carrier conjugates comprising virus like particles and uses thereof
03/18/2004WO2004007697A3 Methods of implanting mesenchymal stem cells for tissue repair and formation
03/18/2004WO2004006952A3 Therapeutic tuberculosis vaccines
03/18/2004WO2004006851A3 Mycoplasma gallisepticum formulation
03/18/2004WO2003097663A3 Immunogenic, monoclonal antibody comprising at least 2 different epitopes of a tumor-associated antigen
03/18/2004WO2003094921A3 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
03/18/2004WO2003093307A3 Mycobacterial antigens and uses thereof
03/18/2004WO2003092714A3 Peptide variants of ige constrained by beta-lactam bond
03/18/2004WO2003092623A3 Calicheamicin derivative-carrier conjugates
03/18/2004WO2003091279A3 COMBINATION VACCINES INCLUDING IMMUNOGENIC GapC AND CAMP FACTOR POLYPEPTIDES
03/18/2004WO2003087146A3 Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism
03/18/2004WO2003082916A3 Tumour associated antigens
03/18/2004WO2003072603A3 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
03/18/2004WO2003065984A3 Methods and compositions for treating cardiovascular disease
03/18/2004WO2003051272A3 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
03/18/2004WO2003047500A3 Vaccine and method for treatment of motor neurone diseases
03/18/2004WO2003047499A3 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
03/18/2004WO2003044172B1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
03/18/2004WO2003040305A3 Porcine adenovirus e1 and e4 regions
03/18/2004WO2003039594A3 Antigen presenting vesicles
03/18/2004WO2003037261A3 Methods and compositions for the treatment and diagnosis of pain disorders using 9805
03/18/2004WO2003032813A3 Methods for the treatment of carcinoma
03/18/2004WO2003028630A3 Methods and compositions for modulating interleukin-21 receptor activity
03/18/2004WO2003007869A3 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
03/18/2004WO2002103029A3 Methods for sterilizing preparations of monoclonal immunoglobulins
03/18/2004WO2002102972A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
03/18/2004WO2002090567A9 Sperm-specific cation channel, and uses therefor
03/18/2004WO2002078516A3 Compositions and methods for the therapy and diagnosis of cancer
03/18/2004WO2002077195A3 Plasmodium falciparum ama-1 protein and uses thereof
03/18/2004US20040055025 Using nuclear transplantation to generate transgenic animal models for harvesting polyclonal antibodies
03/18/2004US20040054159 Use of parapox b2l protein to modify immune responses to administered antigens
03/18/2004US20040054158 GL50 molecules and uses therefor
03/18/2004US20040054149 Modified proteolytic enzyme for treatment of osteoarthritis
03/18/2004US20040054146 Allergy vaccines
03/18/2004US20040054145 Truncated cd200
03/18/2004US20040054142 Cripto tumour polypeptide
03/18/2004US20040054139 Chimeric genetically engineered DNA viral protein for use in immunotherapy and vaccine development
03/18/2004US20040054133 Multiple sclerosis-related superantigen
03/18/2004US20040053880 Nucleic acid compositions for stimulating immune responses
03/18/2004US20040053871 Innoculation by administered polynucleotide codes for epitopes of antigens; DNA vaccines
03/18/2004US20040053867 Nucleotide sequences that code for transport proteins; modulation of excitatory amino acids or signal tranduction; detoxification
03/18/2004US20040053858 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
03/18/2004US20040053843 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
03/18/2004US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds
03/18/2004US20040053822 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
03/18/2004US20040053393 Comprises genetically engineered bacteriophage polymerase for detection and treatment of microorganismal infections
03/18/2004US20040053391 Renal cell carcinoma-antigen G250-derived peptides that elicit both CD4+ and CD8+ T-cell responses
03/18/2004US20040053379 Method of producing polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs
03/18/2004US20040053372 Comprises prothrombin amino acid sequences for treating thrombosis and blood disorders
03/18/2004US20040053316 Contacting composition with an aziridine derivative inactivating agent; killed virus-containing vaccines
03/18/2004US20040053278 Smad6 and uses thereof
03/18/2004US20040053262 Supressor gene
03/18/2004US20040053216 DNA vaccines against hantavirus infections
03/18/2004US20040053208 Methods to selectively inactivate parasites in biological compositions
03/18/2004US20040052895 Comprises colloid extrudate comprising water, carbohydrate, and amino acid sources; vaccines
03/18/2004US20040052864 Comprises decitabine as methylation inhibitor; kits; tumor suppressor genes/proteins; interleukins; vaccines
03/18/2004US20040052820 Peptide containing amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178, inhibitory of human and nonhuman retroviral, especially HIV, transmission to uninfected cells
03/18/2004US20040052818 Flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy terminal hydrophobic region is not affected by the deletion
03/18/2004US20040052817 A nucleic acid sequences encoding Ostertagia ostertagi proteins and parts of such nucleic acid sequences encode an immunogenic fragment of such proteins
03/18/2004US20040052816 Recombinant protective protein from streptococcus pneumoniale
03/18/2004US20040052815 An immunogenic complex characterised in that an enzyme is integrated into an immunostimulating complex (ISCOM) containing a glycoside, a lipid and an antigen
03/18/2004US20040052813 Polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits and the diagnostic kits
03/18/2004US20040052812 Immunogenic complex containing a multi-component viral particle covalently linked to a javelin molecule, wherein the javelin molecule is a peptide which selectively binds to a heat shock protein
03/18/2004US20040052811 Vaccine against cancer diseases that are associated with the her-2/neu oncogene
03/18/2004US20040052809 Atherosclerosis; apolipoproteins; induce immunology response
03/18/2004US20040052808 Nose and skin strip containing allergens; in situ antiinflammatory agents
03/18/2004US20040052807 Synthetic vaccine for tick control
03/18/2004US20040052805 Vaccine complex; forming antibodies
03/18/2004US20040052804 Vaccine complex; induce immunology response; prevent sepsis
03/18/2004US20040052802 Attenuated mutant; prevent inferctions, diarrhea; human and veterinary medicine
03/18/2004US20040052801 Genetic engineered polypeptides
03/18/2004US20040052800 Stabilization of immunogens derived from paramyxoviruses
03/18/2004US20040052799 Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
03/18/2004US20040052796 Anticancer agents; antitumor agents; controlling gene expression; quantitative analysis
03/18/2004US20040052787 Screening for menstruation disorders; measurement nucleic acids or protein
03/18/2004US20040052786 Erbb4 antagonists
03/18/2004US20040052785 Synergistic mixtures; antitumor agents
03/18/2004US20040052781 Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs
03/18/2004US20040052779 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
03/18/2004US20040052775 Antigens; induce immunology response; prevent infections; genetic engineering
03/18/2004US20040052773 Production of multi-chain protein from muscle
03/18/2004US20040052769 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
03/18/2004US20040052766 Alzheimer's disease vaccine; induction antibodies, antigens
03/18/2004US20040052765 Modulate immunology response; isolation nucleic acids; induce immunology response; genetic engineering
03/18/2004US20040052763 Target antigens; vaccine
03/18/2004US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides
03/18/2004US20040050784 Method for the manufacture of compositions containing low concentrations of salts
03/18/2004DE10305607A1 Immunogene MUC1-Glykopeptide Immunogenic MUC1 glycopeptides
03/18/2004DE10242318A1 Orthopoxvirusantigene und deren Verwendung Orthopoxvirusantigene and their use